Investors

Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August 31, 2021 SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics,

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms.

Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in 2021 Strong financial position with $496 million as of May 31, 2021 SAN FRANCISCO, July 13, 2021

SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product

Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc.

NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix management team will participate in the following conferences in May: RBC Capital Markets Global

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after successful $150 million follow-on offering in March 2021 SAN FRANCISCO, April 13, 2021 (GLOBE NEWSWIRE)

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th